Title: Clinical Analysis of Sitagliptin Combined with Acarbose in the Treatment of Refractory Type 2 Diabetes
Abstract: Objective To investigate the clinical value of sitagliptin combined with acarbose in controlling the blood glucose and islet function of patients with refractory type 2 diabetes. Methods A total of 376 cases of refractory type 2 diabetes admitted to Rucheng County People's Hospital from Jan. 2012 to Dec. 2013 were randomly divided into two groups by random number table method,188 cases in each group. Patients in control group were given sitagliptin( 50 mg / time,3 times per day,orally),and patients in observation group were added acarbose( 100 mg / time,1 time per day,orally) on the basis of the treatment of the control group.The efficacy,glycemic index,insulin resistance,insulin β-cell function,and adverse reactions of the two groups after three months of treatment were compared. Results After treatment,the effective rate of the observation group was 93. 6%( 176 /188),significantly higher than the control group' s 82. 4%( 155 /188)( P 0. 05 or P 0. 01). After treatment,fasting blood-glucose,2 hours postprandial blood glucose,and glycosylated hemoglobin levels of the observation group were significantly lower than those in the control group( P 0. 05). Fasting serum insulin,and insulin homeostasis assessment index levels of two groups were significantly reduced and fasting C peptide and pancreatic islet β cell function index levels were significantly improved than before treatment( P 0. 01). The c peptide and insulin β-cell function of the observation group were significantly higher than those in the control group( P 0. 05 or P 0. 01). The incidence of drug-induced hypoglycemia of the observation group was significantly lower than that in the control group( P 0. 05). Conclusion Sitagliptin combined with acarbose can effectively reduce the glycemic level and improve the islet function of patients with refractory type 2 diabetes.
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot